Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Allogeneic Stem Cell Therapy Market

ID: MRFR/HC/34163-HCR
100 Pages
Rahul Gotadki
Last Updated: April 24, 2026

Allogeneic Stem Cell Therapy Market Research Report: Size, Share, Trend Analysis By Types of Stem Cells (Hematopoietic Stem Cells, Mesenchymal Stem Cells, Others), By Applications (Cancer Treatment, Autoimmune Diseases, Cardiovascular Diseases, Orthopedic Disorders), By End Use (Hospitals, Research Institutes, Clinics), By Source of Stem Cells (Bone Marrow, Umbilical Cord Blood, Peripheral Blood) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Allogeneic Stem Cell Therapy Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type of Stem Cells (USD Billion) | |
      1. 4.1.1 Hematopoietic Stem Cells | |
      2. 4.1.2 Mesenchymal Stem Cells | |
      3. 4.1.3 Others |
    2. 4.2 Healthcare, BY Application (USD Billion) | |
      1. 4.2.1 Cancer Treatment | |
      2. 4.2.2 Autoimmune Diseases | |
      3. 4.2.3 Cardiovascular Diseases | |
      4. 4.2.4 Orthopedic Disorders |
    3. 4.3 Healthcare, BY End Use (USD Billion) | |
      1. 4.3.1 Hospitals | |
      2. 4.3.2 Research Institutes | |
      3. 4.3.3 Clinics |
    4. 4.4 Healthcare, BY Source of Stem Cells (USD Billion) | |
      1. 4.4.1 Bone Marrow | |
      2. 4.4.2 Umbilical Cord Blood | |
      3. 4.4.3 Peripheral Blood |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Novartis (CH) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Bristol Myers Squibb (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Gilead Sciences (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Amgen (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Celgene (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Takeda (JP) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Roche (CH) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Sanofi (FR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Allogene Therapeutics (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE OF STEM CELLS |
    7. 6.4 US MARKET ANALYSIS BY APPLICATION |
    8. 6.5 US MARKET ANALYSIS BY END USE |
    9. 6.6 US MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    11. 6.8 CANADA MARKET ANALYSIS BY APPLICATION |
    12. 6.9 CANADA MARKET ANALYSIS BY END USE |
    13. 6.10 CANADA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF STEM CELLS |
    16. 6.13 GERMANY MARKET ANALYSIS BY APPLICATION |
    17. 6.14 GERMANY MARKET ANALYSIS BY END USE |
    18. 6.15 GERMANY MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    19. 6.16 UK MARKET ANALYSIS BY TYPE OF STEM CELLS |
    20. 6.17 UK MARKET ANALYSIS BY APPLICATION |
    21. 6.18 UK MARKET ANALYSIS BY END USE |
    22. 6.19 UK MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF STEM CELLS |
    24. 6.21 FRANCE MARKET ANALYSIS BY APPLICATION |
    25. 6.22 FRANCE MARKET ANALYSIS BY END USE |
    26. 6.23 FRANCE MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    28. 6.25 RUSSIA MARKET ANALYSIS BY APPLICATION |
    29. 6.26 RUSSIA MARKET ANALYSIS BY END USE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF STEM CELLS |
    32. 6.29 ITALY MARKET ANALYSIS BY APPLICATION |
    33. 6.30 ITALY MARKET ANALYSIS BY END USE |
    34. 6.31 ITALY MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF STEM CELLS |
    36. 6.33 SPAIN MARKET ANALYSIS BY APPLICATION |
    37. 6.34 SPAIN MARKET ANALYSIS BY END USE |
    38. 6.35 SPAIN MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF STEM CELLS |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    45. 6.42 CHINA MARKET ANALYSIS BY APPLICATION |
    46. 6.43 CHINA MARKET ANALYSIS BY END USE |
    47. 6.44 CHINA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    49. 6.46 INDIA MARKET ANALYSIS BY APPLICATION |
    50. 6.47 INDIA MARKET ANALYSIS BY END USE |
    51. 6.48 INDIA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF STEM CELLS |
    53. 6.50 JAPAN MARKET ANALYSIS BY APPLICATION |
    54. 6.51 JAPAN MARKET ANALYSIS BY END USE |
    55. 6.52 JAPAN MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY END USE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF STEM CELLS |
    65. 6.62 THAILAND MARKET ANALYSIS BY APPLICATION |
    66. 6.63 THAILAND MARKET ANALYSIS BY END USE |
    67. 6.64 THAILAND MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    69. 6.66 INDONESIA MARKET ANALYSIS BY APPLICATION |
    70. 6.67 INDONESIA MARKET ANALYSIS BY END USE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF STEM CELLS |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY END USE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF STEM CELLS |
    78. 6.75 BRAZIL MARKET ANALYSIS BY APPLICATION |
    79. 6.76 BRAZIL MARKET ANALYSIS BY END USE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF STEM CELLS |
    82. 6.79 MEXICO MARKET ANALYSIS BY APPLICATION |
    83. 6.80 MEXICO MARKET ANALYSIS BY END USE |
    84. 6.81 MEXICO MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY END USE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF STEM CELLS |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF STEM CELLS |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY END USE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY SOURCE OF STEM CELLS |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE OF STEM CELLS, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE OF STEM CELLS, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY SOURCE OF STEM CELLS, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY SOURCE OF STEM CELLS, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE OF STEM CELLS, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END USE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY SOURCE OF STEM CELLS, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type of Stem Cells (USD Billion, 2025-2035)

  • Hematopoietic Stem Cells
  • Mesenchymal Stem Cells
  • Others

Healthcare By Application (USD Billion, 2025-2035)

  • Cancer Treatment
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Orthopedic Disorders

Healthcare By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Research Institutes
  • Clinics

Healthcare By Source of Stem Cells (USD Billion, 2025-2035)

  • Bone Marrow
  • Umbilical Cord Blood
  • Peripheral Blood

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions